Effect of atorvastatin 1% mouthwash in the prevention of radiotherapy induced mucositis: A pilot study

**Abstract**

**Background:** Oral mucositis is a troublesome symptom for people who receive radiotherapy and chemotherapy and it is a dose-dependent factor. Atorvastatin is a HMG-CoA reductase inhibitors and various studies have proven its anti-inflammatory effects. The goal of this study was to evaluate atorvastatin 1% mouthwash effects in prevention of radiotherapy-induced mucositis.

**Methods:** Atorvastatin 1% suspension was prepared for mouthwash in this randomized, double-blind clinical trial. Thirty patients randomly received atorvastatin or placebo mouthwash. They had to gargle 5cc of mouthwash, 3 times per day during radiotherapy. The severity and pain of mucositis was evaluated every week, during their treatment.

**Results:** The severity of mucositis between the two study groups was significant every four weeks (p<0.05) and the percentage of patients with more severe mucositis was less in the atorvastatin group. It is found that the pain intensity was lower after 3 and 4 weeks in atorvastatin group.

**Conclusion:** These findings indicated that atorvastatin mouthwash showed a significant activity in relieving of radiotherapy-induced oral mucositis and pain.

**Keywords:** Atorvastatin, Mouthwash, Oral mucositis, Radiotherapy

**Citation:** Ala S, Saeedi M, Ghasemi A, Namdari M, Koulaeinejad N. Effect of atorvastatin 1% mouthwash in the prevention of radiotherapy induced mucositis: A pilot study. Caspian J Intern Med 2022; 13(4): 800-804.

Each year, many people around the world get cancer. So an approach is required for optimal treatment planning and post-treatment response assessment (1). Radiotherapy is one of the common treatment protocols which may be used alone or in addition to chemotherapy. Some adverse effects such as mucositis may be detected while going through radiotherapy (2).

Oral mucositis occurs in patients receiving conventional-dose cytotoxic chemotherapy and in those who are prepared with radiation-containing regimens (3). It is an indirect effect of radiotherapy which inhibits the oral epithelium cell mitosis and it is usually exposed 7 to 10 days after radiotherapy inception (4). Mucositis formation appears in 5 phases (5). There is no consensus on the best clinical protocol for the prevention and treatment of mucositis (6). Mucositis can also be associated with complications. For this reason, it is necessary to minimize and prevent it as much as possible (6). Atorvastatin is a HMG-CoA reductase inhibitor which inhibits cholesterol biosynthesis. Another use of atorvastatin is its anti-inflammatory impacts (7-11).
This study is a first randomized clinical trial that evaluated the effects of atorvastatin 1% mouthwash on patients diagnosed with different types of cancer, who had already undergone radiotherapy treatment.

**Methods**

The 1% atorvastatin mouthwash was prepared in the Department of Pharmaceutics, Faculty of Pharmacy using the following materials: the appropriate amounts of atorvastatin powder, glycerin, methyl paraben, PEG 200, xanthan gum, sodium saccharin, tween 80 and distilled water. The content of atorvastatin suspension was determined at 24, 48 and 72 hour and compared with initial content. The placebo was prepared according to the same method, but atorvastatin was not added to the mouthwash. The final preparations were filled in the same bottles and labeled. Both mouthwashes were similar in color, odor and taste.

This randomized, placebo-controlled, double-blind clinical trial was carried out in Radiotherapy Center of Imam Khomeini Educational Hospital of Mazandaran University of Medical Sciences, Sari, Iran. This study was in accordance with Declaration of Helsinki.

The trial registration code is IRCT201502033014N6. Also, the ethical approval number is IR.MAZUMS.REC.1393.1420. All patients gave written informed consent before enrolment. Also, they were informed that at any time they did not want to continue the trial, we excluded them from the study.

All patients with cancer, especially with head and neck who experienced radiotherapy-induced mucositis for the first time and were older than 18 years were included in this study. Drug intolerance before first week, incorrect use of mouthwash, receiving oral atorvastatin and anti-inflammatory drugs, history of chemotherapy and development of mucositis (deterioration of mucositis grade during the trial) were the exclusion criteria. Patients received radiotherapy daily for 4 weeks (other than Thursdays and Fridays).

A Siemens PRIMUSTM linac dual energy machine operating in the 6MVphoton mode was used. The average dose used was 63 Gy. The radiotherapy site was the mouth and throat.

Simple randomization was performed using a table of random numbers. This procedure was carried out by a researcher which he did not attend in subsequent parts of the study. People who went blind in this study included the patients, attending physician and investigators.

Immediately upon starting the radiotherapy sessions, the mouthwash was given to the patients. The patients had to gargle with 5 cc of mouthwash 3 times a day, for at least 5 min, but not to swallow. When the patients referred to Mostafavi Clinic of Mazandaran University of Medical Sciences, they were evaluated by the researcher.

As described below, WHO scoring was used to assess mucosal severity: Grade 0 (none): None. Grade I (mild): Oral soreness, erythema. Grade II (moderate): Oral erythema, ulcers, solid diet tolerated. Grade III (severe): Oral ulcers, liquid diet only. Grade IV (life-threatening): Oral alimentation impossible (12).

All patients were checked every 7 days during the radiotherapy treatment in terms of mucositis development and changes in oral cavity tissues. The inflammation, erythema, bleeding, infection and liquid and solid swallowing ability were assessed. Also, the pain intensity was evaluated by a visual analogue scale. The highest score 10 representing intolerable pain and 0 showing the absence of pain. The blood tests were also collected to determine serum creatinine and hemoglobin, white blood cells, platelet and blood urea nitrogen at baseline.

**Results**

As depicted in fig.1, of the 54 eligible patients, 18 patients were not randomized because of the decline to participate and did not have the inclusion criteria. Full details of demographic characteristics, basal hematological test data and distribution of different types of cancers are represented in table 1. According to table 2, there was a significant difference between the two study groups in the whole four weeks. The intensity of mucositis-associated pain are shown in figure 2.
Figure 1. Consort flowchart of the study

Table 1. Baseline characteristics of patients

| Variables                        | Atorvastatin | Placebo | P-value |
|----------------------------------|--------------|---------|---------|
| Number of patients               | 17           | 13      |         |
| Age (Y), (Mean ± SD)             | 53.5±15.08   | 62.5±12.6 | 0.4    |
| Sex (Male/Female), n             | 11/6         | 4/9     | 0.07    |
| Laboratory test values (Mean±SD) |              |         |         |
| WBC (10^3 /mm³)                  | 5.8 ± 1.7    | 9.2 ± 1.0 | 0.4    |
| BUN (mg/dl)                      | 20.4 ± 3.9   | 19.1 ± 3.7 | 0.5    |
| PLT (10^3 /mm³)                  | 230 ± 63     | 254 ± 98 | 0.4    |
| Hb (g/dl)                        | 12.14 ± 1.78 | 12.1 ± 1.15 | 0.5    |
| SCr (mg/dl)                      | 1 ± 0.29     | 0.8 ± 0.13 | 0.6    |
| Type of cancer, N (%)            |              |         |         |
| Tongue s.c.c                     | 6 (35.3)     | 3 (23.1) |         |
| Hodgkin’s lymphoma               | 3 (17.6)     | 2 (15.4) |         |
| Lymphoma                         | 1 (5.9)      | 1 (7.7)  |         |
| Nasopharynx cancer               | 5 (29.4)     | 3 (23.1) |         |
| Multiple myeloma                 | 1 (5.9)      | 0 (0)    | 0.12    |
| Cervical mass                    | 1 (5.9)      | 1 (7.7)  |         |
| Larynx cancer                    | 0 (0)        | 1 (7.7)  |         |
| Submandibular lymphoma           | 0 (0)        | 1 (7.7)  |         |
| Esophagus cancer                 | 0 (0)        | 1 (7.7)  |         |

WBC: white blood cells, BUN: blood urea Nitrogen, PLT: platelet, Hb: serum hemoglobin, SCr: serum creatinine
Atorvastatin 1% mouthwash and prevention of radiotherapy induced mucositis

Table 2. Severity of mucositis in the two study groups at different time points

| Time (week) | Grade | Atorvastatin, n (%) | Placebo, n (%) | P-value |
|-------------|-------|---------------------|----------------|---------|
| 0           | 15 (88.2%) | 4 (30.8%)          |                |         |
| 1           | 1 (5.9%)   | 9 (69.2%)           |                |         |
| 2           | 0 (0)      | 1 (7.7%)            |                | 0.001   |
| 3           | 4 (23.5%)  | 0 (0)               |                |         |
| 4           | 1 (5.9%)   | 0 (0)               |                |         |

Figure 2. Pain intensity (VAS) on different weeks in atorvastatin mouthwash 1% and placebo groups.

* p<0.05, ** p<0.01

Discussion

By studying the degree of mucositis in two groups of patients, atorvastatin recipient showed a significant decrease. The frequency of mucositis manifestation in atorvastatin group was significantly less in comparison with placebo group. In the total 4 weeks (p<0.05), according to other results farther than mucositis severity, there was a significant difference in pain frequency. Atorvastatin mouthwash reduced pain after third and fourth weeks. One of the theories about this effect is also the inflammation decrease by...
atorvastatin. As mentioned above, since one of the main mucositis causes is increasing inflammatory markers such as IL-2, IL-6 and etc, anti-inflammatory effects of atorvastatin is justifiable. The results of this study are in agreement with several other studies as follows. In 2018, Özdoğan et al. evaluated the effects of locally administration of atorvastatin (2% w/v) containing chitosan formulations in the treatment of periodontitis in rats. The administration of atorvastatin could decrease the release of pro-inflammatory cytokines. Also, the alveolar bone healing was significant (13).

To the best of our knowledge, this study is the first to evaluate atorvastatin mouthwash in the prevention of radiotherapy-induced mucositis. Nevertheless, our study has few limitations. Patients’ nutritional status was not evaluated. This item can affect developing or haling of mucositis. Small sample size is another limitation of our study. It is suggested that larger studies with severity assessment of other mucositis problems for example pain, be conducted in the future. In conclusion atorvastatin 1% mouthwash could effectively reduce pain, erythema and ultimately, mucositis in comparison with placebo group with significant difference.

Acknowledgments
The authors acknowledge the vice chancellor of Research and Technology Affairs of Mazandaran University of Medical Sciences for financial support.

Funding: This study was supported by the Vice-Chancellery for Research of Mazandaran University of Medical Sciences under grant number 1420 and was Melika Namdari’s doctoral thesis.

Conflict of Interest: None declared.

Authors’ contribution: Shahram Ala, Maid Saeedi and Arash Ghasemi conceived of the study. Shahram Ala, Maid Saeedi, Arash Ghasemi and Neda Koulaeinejad initiated the study design and Melika Namdari helped with implementation. Shahram Ala and Arash Ghasemi analysed the data. Melika Namdari and Neda Koulaeinejad performed the measurements and designed the figures. All authors contributed to refinement of the study protocol and approved the final manuscript.

References
1. Wheless SA, McKinney KA, Zanation AM. A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol Head Neck Surg 2010; 143: 650-4.
2. McQuaid D, Dunlop A, Nill S, et al. Evaluation of radiotherapy techniques for radical treatment of lateralised oropharyngeal cancers: Dosimetry and NTCP. Strahlenther Onkol 2016; 192: 516-25.
3. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4: 277-84.
4. Sonis ST, Tracey C, Shklar G, Jenson J, Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1990; 69: 437-43.
5. Rodriguez-Caballero A, Torres-Lagares D, Robles-García M, et al. Cancer treatment-induced oral mucositis: a critical review. Int J Oral Maxillofac Surg 2012; 41: 225-38.
6. Moslemi D, Nokhandani AM, Otaghsareai MT, et al. Management of chemo/radiation-induced oral mucositis in patients with head and neck cancer: A review of the current literature. Radiother Oncol 2016; 120: 13-20.
7. Kastrup EK, Boyd JR. Facts and Comparisons: Drug Information 1979 Edition. AJN Am J Nurs 1979; 79: 1321-35.
8. Lacy CF, Armstrong LL, Lance LL, Goldman MP. Drug information handbook with international trade names index. 25th ed. US: Lexi-Comp Incorporated 2016; pp: 187-90.
9. Nikookar SH, Hajheydari Z, Moosa-Kazemi SH, Mahmoudi M, Shahmohammadi S. Comparison of topical trimcinolone and oral atorvastatin in treatment of Paederus dermatitis northern Iran. Pakistan J Biol Sci 2012; 15: 103-7.
10. Steiner S, Speidi WS, Pleiner J, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111: 1841-6.
11. Zamani E, Mohammadbagheri M, Fallah M, Shaki F. Atorvastatin attenuates ethanol-induced hepatotoxicity via antioxidant and anti-inflammatory mechanisms. Res Pharm Sci 2017; 12: 315-21.
12. Peterson D, Boers-Doets C, Bensadoun R, Herrstedt J. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 2015; 26: v139-v51.
13. Özdoğan Al, Akca G, Şenel S. Development and in vitro evaluation of chitosan based system for local delivery of atorvastatin for treatment of periodontitis. Eur J Pharm Sci 2018; 124: 208-16.
Atorvastatin 1% mouthwash and prevention of radiotherapy induced mucositis